Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, it is non-specific and can be linked to other, more widespread medical conditions. AML is one of the four common types of leukemia in adults. It occurs less frequently. It is slightly more common among men than women, however, the average lifetime risk of getting AML in both sexes is about ½ of 1% on average.
AML is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. Rising maternal obesity rates may be partially responsible for the rise in the prevalence of AML.
Due to various risk factors, AML incidence has been rising, becoming a significant socio-economic issue. This is expected to act as a driver for market growth
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-acute-myeloid-leukemia-diagnostics-market
Data Bridge Market Research analyses that the Global Acute Myeloid Leukemia Diagnostics Market is expected to grow with a CAGR of 11.3% in the forecast period of 2024 to 2031 and is expected to reach USD 6,538.78 million by 2031 from USD 2,777.16 million in 2023.
Key Findings of the Study
Novel Technological Advancements in Leukemia Diagnostics
The most common form of blood cancer, AML, is also one of the uncommon forms of leukemia. This form of cancer invades in blood, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.
The risk of prescribing incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the devastating effects of leukemia disease. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.aw
The development of several new diagnostic methods will increase the market growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnostic products in the market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable into 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (65 and Above, Below 21, 21-29, and 30-65), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Vietnam, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
CANON MEDICAL SYSTEMS CORPORATION (Japan), Sysmex Corporation (Japan), Epigenomics AG (Germany), Myriad Genetics, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), QIAGEN (U.S.), Agilent Technologies, Inc. (U.S.), Siemens Healthcare GmbH (Germany), BIOMERIEUX (France), Exact Sciences Corporation (U.S.), Merck KGaA, Hologic Inc. (U.S.), DiaSorin S.p.A. (Italy), Illumina, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), BD (U.S.), Quest Diagnostics Incorporated (U.S.), Bio-Rad Laboratories, Inc. (U.S.), FONAR Corp., Time Medical Holding.(Hong Kong), Sonic Healthcare (Australia), PlexBio (Taiwan), MinFound Medical Systems Co., Ltd (China), Medonica Co. Ltd (Korea), Thermo Fisher Scientific Inc. (U.S.), and SternMed GmbH (Germany) among others
|
Segment Analysis
The global acute myeloid leukemia diagnostics market is segmented into seven notable segments based on product type, test type, cancer type, age group, gender, end user, and distribution channel.
- On the basis of product type, the global acute myeloid leukemia diagnostics market is segmented into instruments and consumables & accessories
In 2024, instruments segment is expected to dominate the global acute myeloid leukemia diagnostics market
In 2024, instruments segment is expected to dominate the market with a 68.91% share owing to the Increase in awareness regarding leukemia cancer
- On the basis of test type, the market is segmented into blood test, imaging test, bone marrow test, genetic tests, biomarker test, immunophenotyping, and others
In 2024, blood test segment is expected to dominate the global acute myeloid leukemia diagnostics market
In 2024, blood test segment is expected to dominate the market with a 31.22% share due to rising preference for preventive health check-ups
- On the basis of cancer type, the market is segmented into myeloblastic (M0), myeloblastic (M1), myeloblastic (M2), promyelocytic (M3), myelomonocytic (M4), monocytic (M5), erythroleukemia (M6), and megakaryocytic (M7). In 2024, myeloblastic (M0) segment is expected to dominate the market with a 29.29% share
- On the basis of age group, the market is segmented into below 21, 21-29, 30-65, and 65 and above. In 2024, 65 and above segment is expected to dominate the market with a 77.34% share
- On the basis of gender, the market is segmented into male and female. In 2024, male segment is expected to dominate the market with a 58.85% share
- On the basis of end user, the market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others. In 2024, hospitals is expected to dominate the market with a 64.89% share
- On the basis of distribution channel, the market is segmented into direct tender and retail sales. In 2024, domestic segment is expected to dominate the market with a 68.26% share
Major Players
Data Bridge market research analyzes CANON MEDICAL SYSTEMS CORPORATION (Japan), Sysmex Corporation (Japan), Epigenomics AG (Germany), Myriad Genetics, Inc. (U.S.), and F. Hoffmann-La Roche Ltd (Switzerland) as the major companies operating in the market.
Market Development
- In November 2022, Canon Inc. acquired Redlen Technologies Inc. (Redlen), one of the world's leading companies in creating new technologies related to the development and manufacture of semiconductor detector modules. Canon Medical Systems Corporation (Canon Medical), a group company of Canon Inc., has developed the first domestically produced Photon-Counting CT (PCCT) system incorporating Redlen's advanced technologies. This system has been installed at the National Cancer Center (NCC) Exploratory Oncology Research & Clinical Trial Center in Japan, where it is currently used to conduct research exploring the clinical applications of PCCT
- In October 2022, Sysmex Corporation Chairman and its CEO: Hisashi Ietsugu announces the approval, of an application for a partial change to the manufacturing and marketing approval in Japan of its gene amplification reagent LYNOAMP CK19 marketed as a lymph node metastasis test reagent for breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, expanding its amplification to cervical cancer and endometrial cancer
- In September 2022, Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG, announced it has enrolled its first subject in a new pivotal clinical trial supporting the Company’s “Next-Generation” blood-based diagnostic screening test for the detection of colorectal cancer (CRC)
- In November 2022, Abbott has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world. This has helped the company to increase its global presence in the market
- In August 2022, Bio-Rad Laboratories Inc. completed its acquisition of Curiosity Diagnostics which is a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and global presence in the market
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Vietnam, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global acute myeloid leukemia diagnostics market
North America is expected to dominate in the global acute myeloid leukemia diagnostics market because of the higher level of investments by various manufacturers and increasing technological advancements in the region.
Asia-Pacific is expected to be the fastest growing region in the global acute myeloid leukemia diagnostics market
Asia-Pacific will continue to be the fastest growing country in the global acute myeloid leukemia diagnostics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
For more detailed information about the global acute myeloid leukemia diagnostics market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-acute-myeloid-leukemia-diagnostics-market
